Floatz logo

Recombinant Fowlpox-Cea/Tricom Vaccine

Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Extensive Stage Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Zhou Chengzhi
Phase 2BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN PROGRAMMED DEATH-LIGAND 1) (HUMAN MONOCLONAL ZKAB001 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL ZKAB001 .LAMBDA.-CHAIN, DIMER
Lee's Pharmaceutical Limited
Phase 3BB
7-hydroxystaurosporine
National Cancer Institute (NCI)
Phase 2BB
(R)-GOSSYPOL ACETIC ACID
National Cancer Institute (NCI)
Phase 2BB
Sorafenib
Peking Union Medical College Hospital
Phase 2/3B

View all 27 →

Same molecule, other indications

Recombinant Fowlpox-Cea/Tricom Vaccine is also rated in:

Breast CancerDormant
CC
Indicative ·
47 / 100
View asset →
Metastases, NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Recurrent Colon CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →